Ontology highlight
ABSTRACT: Background
People with opioid dependence and HIV are concentrated within criminal justice settings (CJS). Upon release, however, drug relapse is common and contributes to poor HIV treatment outcomes, increased HIV transmission risk, reincarceration and mortality. Extended-release naltrexone (XR-NTX) is an evidence-based treatment for opioid dependence, yet is not routinely available for CJS populations.Methods
A randomized, double-blind, placebo-controlled trial of XR-NTX for HIV-infected inmates transitioning from correctional to community settings is underway to assess its impact on HIV and opioid-relapse outcomes.Results
We describe the methods and early acceptability of this trial. In addition we provide protocol details to safely administer XR-NTX near communit
SUBMITTER: Di Paola A
PROVIDER: S-EPMC4283549 | biostudies-literature | 2014 Nov
REPOSITORIES: biostudies-literature